ERBB2 status and benefit from adjuvant tamoxifen in ERalpha-positive postmenopausal breast carcinoma.

We examined the relation between ERBB2 gene expression (as determined by a real-time quantitative RT-PCR assay) and the response to adjuvant tamoxifen therapy in a well-defined cohort of 125 ERalpha-positive postmenopausal patients with breast cancer. Although ERBB2 overexpression was associated with shorter relapse-free survival in univariate analysis (P=0.00029), ERBB2 did not persist as an independent prognostic factor in multivariate analysis. Nevertheless, when we analyzed the ERBB2 mRNA level as a continuous variable, the higher the ERBB2RNA level, the poorer the outcome (P=0.00036). The results point to the need for a quantitative ERBB2 expression assay for use in future studies of ERBB2-based clinical management of breast cancer.

[1]  J. Cairns,et al.  Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. , 1992, British Journal of Cancer.

[2]  I. Bièche,et al.  Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications. , 1999, Clinical chemistry.

[3]  D. Miles,et al.  Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer , 1999, British Journal of Cancer.

[4]  M. Fernö,et al.  ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  R. Elledge,et al.  Tumor characteristics and clinical outcome of elderly women with breast cancer. , 2000, Journal of the National Cancer Institute.

[6]  I. Ellis,et al.  Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. , 1995, British Journal of Cancer.

[7]  S. Martino,et al.  HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  M. Dowsett,et al.  Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  M. Sliwkowski,et al.  HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. , 1995, Oncogene.

[10]  L. Holmberg,et al.  Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[12]  A. Bianco,et al.  c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  B. Têtu,et al.  Prognostic significance of HER‐2/neu oncoprotein expression in node‐positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy , 1994, Cancer.

[14]  D. Cox.  Regression Models and Life-Tables , 1972 .

[15]  M. Fernö,et al.  ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. , 1994, Cancer letters.